A Study Based on CT Radiomics for Distinguishing Benign From Malignant Renal Tumors and Assessing Their Aggressiveness.

NCT07060248 | Active Not Recruiting DMC

• 1 other identifier: JLiu
• Study Type: observational
• Target: 700
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the efficacy of CT-based radiomics in differentiating benign from malignant renal tumors, predicting nuclear grading of renal cell carcinoma, and assessing T-stage of renal tumors, thereby exploring its clinical application value.

Conditions

Renal Cell Carcinoma (RCC)

Outcome Measures

Primary Outcomes (3)

• CT-based radiomics analysis for benign and malignant tumor differentiation

  Histopathological diagnosis served as the gold standard, with tumors classified into: (1) Benign renal tumors: Including lipid-poor angiomyolipoma and renal oncocytoma; (2) Malignant renal tumors: Comprising clear cell renal cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma

  within 1 month

• CT-based radiomics analysis for nuclear grading of clear cell renal cell carcinoma (ccRCC)

  Histopathological diagnosis served as the gold standard, with tumors classified into: (1) low grade ccRCC: Including WHO/ISUP grade 1-2 ccRCC; (2) high grade ccRCC: Including WHO/ISUP grade 3-4 ccRCC

  within 1 month

• CT-based radiomics analysis of T-stage classification of renal cell carcinoma (RCC)

  Histopathological diagnosis served as the gold standard, with tumors classified into: (1) low T-stage RCC: Including T1-2 RCC; (2) high T-stage RCC: including T3-4 RCC

  within 1 month

Study Arms (1)

RCC group, non-RCC group; WHO/ISUP low-grade ccRCC, high-grade ccRCC; T3 tumor, T1-T2 tumor

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with renal mass

You may qualify if:

• Pathologically confirmed renal tumors (including clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, angiomyolipoma, and oncocytoma).
• Contrast-enhanced CT scan was performed preoperatively.

You may not qualify if:

• Pure cystic clear cell renal cell carcinoma
• Poor-quality CT images

Sponsors & Collaborators

• Second Xiangya Hospital of Central South University: lead

Study Sites (1)

Second Xiangya Hospital

Changsha, Hunan, China

Location

MeSH Terms

Conditions

Carcinoma, Renal Cell

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Kidney Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 23, 2025
• First Posted: July 11, 2025
• Study Start: January 1, 2025
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): June 30, 2027
• Last Updated: July 11, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)